Johannesburg, 17 April 2026: Sibanye-Stillwater (JSE: SSW and NYSE: SBSW) and the South African Nuclear Energy Corporation SOC Ltd (Necsa) are pleased to announce their research collaboration. The collaboration aims to advance the development of a radioactive palladium isotope derived from rhodium for use in Targeted Radionuclide Therapy. The radioactive isotope Palladium-103 is currently used in Brachytherapy to treat localised tumours, including prostate cancer, by delivering radiation directly to the affected area, thereby limiting exposure to surrounding healthy tissue.
Rhodium is a platinum group metal (PGM) produced and refined by Sibanye-Stillwater at its South African operations. Under the first phase of the project, Necsa will test and verify that the rhodium meets radionuclide production standards and will conduct further chemical work, including the production of high purity Palladium-103 (Pd-103), that could eventually be used in Targeted Radionuclide Therapy. The second phase of the project will see the parties collaborate on developing other nuclear medicine applications using rhodium and other PGMs produced by Sibanye-Stillwater. PGMs are already used in a range of medical applications, including diagnostic imaging and medical devices.
